Abstract
Rheumatoid Arthritis (RA) is an autoimmune disease that causes cartilage and bone damage relationated with incapacitation. Studies have shown that osteoclasts inhibition reduces bone loss in RA. Denosumab, a monoclonal antibody anti-receptor activator of nuclear factor kappa-’ ligand (RANKL), is used as RA treatment, since the binding of RANKL to receptor activator of nuclear factor kappa…